Where does EpiVax Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), EpiVax Inc. ranks #13,973 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does EpiVax Inc. hold?

EpiVax Inc. holds 21 US utility patents granted between 2019 and 2025, spanning 7 technology areas.

What is EpiVax Inc.'s Innovation Score?

EpiVax Inc. has an Innovation Score of 30.2 out of 100 (33rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does EpiVax Inc. focus on?

EpiVax Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 21 patents, ranking #1,078 of 7,163 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is EpiVax Inc.'s patent grant rate increasing or decreasing?

EpiVax Inc.'s recent grant velocity is +750% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for EpiVax Inc.'s patents?

EpiVax Inc.'s patents average 12.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the EpiVax Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

EpiVax Inc.

USPTO PatentsView assignee record - 21 granted patents across 7 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Epivax ranks #13,973 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 7 technology areas.

#13,973
of 49,997 US assignees by volume: 33rd percentile
by Innovation Score (30.2/100): 12.9
avg claims per patent: +750%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13973 · US Corporation #13,973 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,973/49,997
PHOTO-FINISH Emerson Climate…
CPC-NARROW A61K · 7 areas
INNOV-THIN 30.2/100
CLAIMS-RICH 12.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +750% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Emerson Climate Technologies (Suzhou) Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Epivax’s 30.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (35%) Velocity 2.4 pts (8%) Breadth 9.4 pts (31%) Claim depth 7.8 pts (26%)

Qualcomm Incorporated · highest

85
EpiVax · this assignee

30
3D Lighting… · lowest

7

What this shows Epivax's Innovation Score is 30.2/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Epivax?

Each dot is one of Epivax’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Epivax’s own 12.9 claims/patent is at or below the 14.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Epivax vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Epivax's grants concentrate

EpiVax Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2021 (10 grants) versus a trough of 1 in 2022. By volume, Epivax sits between Emerson Climate Technologies (Suzhou) Co., Ltd. and Exabeam, Inc..

Epivax's three-year grant acceleration

EpiVax Inc. shows 5 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Emerson Climate (…

21
Enpower

21
Enable Injections

21
Energy Full

21
Erber

21
Etagen

21
Evonik Oxeno & KG

21
Exabeam

21
Epivax ◀

21

What this shows EpiVax holds 21 patents at rank #13,975, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near EpiVax

By rank, the assignees closest to #13,975 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in EpiVax's primary technology class.

Epivax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

EpiVax Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	9.5%
2020	2	9.5%
2021	10	47.6%
2022	1	4.8%
2023	2	9.5%
2024	2	9.5%
2025partial year	2	9.5%

Which technologies does EpiVax Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 21

C07K - Peptides 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C12Y - Enzymes 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

EpiVax Inc.'s patent record in context - here's where to go next.

EpiVax Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #13,973 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare EpiVax Inc. against Emerson Climate Technologies (Suzhou) Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.